AAAAAA
Results: 1-25/39
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, Re: Role of the heat shock response and molecular chaperones in oncogenesis and cell death, J NAT CANC, 93(3), 2001, pp. 239-240
Authors:
Liu, YQ
Kyle, E
Patel, S
Housseau, F
Hakim, F
Lieberman, R
Pins, M
Blagosklonny, MV
Bergan, RC
Citation: Yq. Liu et al., Prostate cancer chemoprevention agents exhibit selective activity against early stage prostate cancer cells, PROSTATE C, 4(2), 2001, pp. 81-91
Authors:
Kang, MH
Figg, WD
Ando, Y
Blagosklonny, MV
Liewehr, D
Fojo, T
Bates, SE
Citation: Mh. Kang et al., The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6 alpha-hydroxypaclitaxel, a major metabolite of paclitaxel, CLIN CANC R, 7(6), 2001, pp. 1610-1617
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, Hypoxia-inducible factor: Achilles' heel of antiangiogenic cancer therapy (Review), INT J ONCOL, 19(2), 2001, pp. 257-262
Authors:
Blagosklonny, MV
Dixon, SC
Robey, R
Figg, WD
Citation: Mv. Blagosklonny et al., Resistance to growth inhibitory and apoptotic effects of phorbol ester andUCN-01 in aggressive cancer cell lines, INT J ONCOL, 18(4), 2001, pp. 697-704
Authors:
Nicoletti, MI
Myers, TG
Fojo, T
Blagosklonny, MV
Citation: Mi. Nicoletti et al., Wild-type p53 marginally induces endogenous MDR-1 mRNA without causing a measurable drug resistance in human cancer cells, INT J ONCOL, 18(2), 2001, pp. 375-381
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, Do VHL and HIF-1 mirror p53 and Mdm-2? Degradation-transactivation loops of oncoproteins and tumor suppressors, ONCOGENE, 20(3), 2001, pp. 395-398
Authors:
Giannakakou, P
Robey, R
Fojo, T
Blagosklonny, MV
Citation: P. Giannakakou et al., Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity, ONCOGENE, 20(29), 2001, pp. 3806-3813
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, Unwinding the loop of Bcl-2 phosphorylation, LEUKEMIA, 15(6), 2001, pp. 869-874
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells, LEUKEMIA, 15(6), 2001, pp. 936-941
Authors:
Blagosklonny, MV
Fojo, T
Bhalla, KN
Kim, JS
Trepel, JB
Figg, WD
Rivera, Y
Neckers, LM
Citation: Mv. Blagosklonny et al., The Hsp90 inhibitor geldanamycin selectively sensitizes Bcr-Abl-expressingleukemia cells to cytotoxic chemotherapy, LEUKEMIA, 15(10), 2001, pp. 1537-1543
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, Paradox of Bcl-2 (and p53): why may apoptosis-regulating proteins be irrelevant to cell death?, BIOESSAYS, 23(10), 2001, pp. 947-953
Authors:
Blagosklonny, MV
Giannakakou, P
Romanova, LY
Ryan, KM
Vousden, KH
Fojo, T
Citation: Mv. Blagosklonny et al., Inhibition of HIF-1-and wild-type p53-stimulated transcription by codon Arg175 p53 mutants with selective loss of functions, CARCINOGENE, 22(6), 2001, pp. 861-867
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, How carcinogens (or telomere dysfunction) induce genetic instability: associated-selection model, FEBS LETTER, 506(3), 2001, pp. 169-172
Authors:
Blagosklonny, MV
Pardee, AB
Citation: Mv. Blagosklonny et Ab. Pardee, Exploiting cancer cell cycling for selective protection of normal cells, CANCER RES, 61(11), 2001, pp. 4301-4305
Authors:
Giannakakou, P
Sackett, DL
Ward, Y
Webster, KR
Blagosklonny, MV
Fojo, T
Citation: P. Giannakakou et al., p53 is associated with cellular microtubules and is transported to the nucleus by dynein, NAT CELL BI, 2(10), 2000, pp. 709-717
Authors:
Kim, JS
Pirnia, F
Choi, YH
Nguyen, P
Knepper, B
Tsokos, M
Schulte, TW
Birrer, MJ
Blagosklonny, MV
Schaefer, O
Mushinski, JF
Trepel, JB
Citation: Js. Kim et al., Lovastatin induces apoptosis in a primitive neuroectodermal tumor cell line in association with RB down-regulation and loss of the G-1 checkpoint, ONCOGENE, 19(52), 2000, pp. 6082-6090
Authors:
Giannakakou, P
Poy, G
Zhan, ZR
Knutsen, T
Blagosklonny, MV
Fojo, T
Citation: P. Giannakakou et al., Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer, ONCOGENE, 19(27), 2000, pp. 3078-3085
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, p53 from complexity to simplicity: mutant p53 stabilization, gain-of-function, and dominant-negative effect, FASEB J, 14(13), 2000, pp. 1901-1907
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, Spotlight on apoptosis, LEUKEMIA, 14(8), 2000, pp. 1500-1501
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, Cell death beyond apoptosis, LEUKEMIA, 14(8), 2000, pp. 1502-1508
Authors:
An, WG
Hwang, SG
Trepel, JB
Blagosklonny, MV
Citation: Wg. An et al., Protease inhibitor-induced apoptosis: accumulation of wt p53, p21(WAF1/CIP1) and induction of apoptosis are independent markers of proteasome inhibition, LEUKEMIA, 14(7), 2000, pp. 1276-1283
Authors:
Blagosklonny, MV
Citation: Mv. Blagosklonny, The dilemma of apoptosis in myelodysplasia and leukemia: a new promise of therapeutic intervention?, LEUKEMIA, 14(12), 2000, pp. 2017-2018
Authors:
Blagosklonny, MV
Dixon, SC
Figg, WD
Citation: Mv. Blagosklonny et al., Efficacy of microtubule-active drugs followed by ketoconazole in human metastatic prostate cancer cell lines, J UROL, 163(3), 2000, pp. 1022-1026
Authors:
Blagosklonny, MV
Robey, R
Bates, S
Fojo, T
Citation: Mv. Blagosklonny et al., Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs, J CLIN INV, 105(4), 2000, pp. 533-539